Chen and coworkers recently indicated the high efficacy of anti- PD-1 treatment after failure of anti- PD-L1 therapy in relapsed/refractory HL, although the patient group in this study was of limited size (35). The gene discussed is CD274; the disease is Hodgkins lymphoma.